Valutazione costo-efficacia del percorso dei pazienti a rischio di epatite B sottoposti a test anti-HBV

Background Currently, guidelines for the management of hepatitis B virus (HBV) infection recommend using the vaccine; however the screening test among not vaccinated people seems to be useful to identify people with clear presence of the virus without disease symptoms. Thanks to the screening test, people infected with HBV are administered conventional therapy in order to stop the progression to cirrhosis, liver failure and hepatocellular carcinoma (HCC). These diseases cause a decrease of QoL and a high consumption of resources for the health system.